Caricamento...
Sunitinib side effects as surrogate biomarkers of efficacy
With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse...
Salvato in:
| Pubblicato in: | Can Urol Assoc J |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Canadian Medical Association
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215302/ https://ncbi.nlm.nih.gov/pubmed/28096937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4315 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|